Literature DB >> 3575379

A long-lasting cholinesterase inhibitor affecting neural and behavioral processes.

M Brufani, C Castellano, M Marta, A Oliverio, P G Pagella, F Pavone, M Pomponi, P L Rugarli.   

Abstract

A series of analogues of physostigmine were prepared with the aim of investigating their inhibitory effects on acetylcholinesterase in the treatment of Alzheimer's disease. One of the isomers prepared was evaluated for its anticholinesterase activity in vivo, acute toxicity, and some behavioral effects. This compound was a competitive inhibitor of the enzyme and was found to antagonize the stimulating effect produced by scopolamine on locomotor activity and to facilitate memory consolidation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3575379     DOI: 10.1016/0091-3057(87)90176-6

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  8 in total

1.  Kinetics of cholinesterase inhibition by eptastigmine in man.

Authors:  L K Unni; V Hutt; B P Imbimbo; R E Becker
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

2.  Long-acting anticholinesterases for myasthenia gravis: synthesis and activities of quaternary phenylcarbamates of neostigmine, pyridostigmine and physostigmine.

Authors:  Qian-Sheng Yu; Harold W Holloway; Weiming Luo; Debomoy K Lahiri; Arnold Brossi; Nigel H Greig
Journal:  Bioorg Med Chem       Date:  2010-05-12       Impact factor: 3.641

3.  Effect of physostigmine on memory consolidation and retrieval processes in intact and nucleus basalis-lesioned rats.

Authors:  A C Santucci; P D Kanof; V Haroutunian
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat.

Authors:  P De Sarno; M Pomponi; E Giacobini; X C Tang; E Williams
Journal:  Neurochem Res       Date:  1989-10       Impact factor: 3.996

Review 5.  Recent Advances in Biocatalysis for Drug Synthesis.

Authors:  Alina Kinner; Philipp Nerke; Regine Siedentop; Till Steinmetz; Thomas Classen; Katrin Rosenthal; Markus Nett; Jörg Pietruszka; Stephan Lütz
Journal:  Biomedicines       Date:  2022-04-21

6.  Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.

Authors:  S Iijima; N H Greig; P Garofalo; E L Spangler; B Heller; A Brossi; D K Ingram
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

7.  Pharmacodynamics and pharmacokinetics of eptastigmine in elderly subjects.

Authors:  A Auteri; A Mosca; N Lattuada; M Luzzana; L Zecca; D Radice; B P Imbimbo
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.